The impact of diabetic glucose concentration on viability and cardiac differentiation of mesenchymal stem cells

Hyperglycemia may be a stumbling block for delivery of regenerative benefits of mesenchymal stem cells (MSCs) to diabetic patients with cardiovascular diseases. Our study aims to assess the viability and cardiac differentiation potential of MSCs after being exposed to diabetic glucose concentration. MSCs were extracted from rat bone marrow. Cells were characterized based on morphology, differentiation potential, and expression of mesenchymal specific markers. MTT assay was done to evaluate the viability of MSCs after treatment with different glucose concentrations. Case group was MSCs treated with diabetic concentration of glucose versus cells treated with PBS as the control group. Growth curve and population doubling time were calculated in both groups. Expression of GATA4 and troponin, as the early and late markers during cardiac differentiation, were measured following 5-azacytidine exposure. Proliferated cells at passage three had fibroblastic-shape, was able to differentiate into adipocytes or osteocytes, and expressed CD73 and CD90. MSCs viability was gradually decreased by increasing glucose concentration. Irrespective of nicotine concentration, three-day exposure imposed more severe detrimental effects on viability compared with one-day treatment. Proliferation rate of the MSCs was lower in the case group, and they need more time for population doubling. Expression of both cardiac markers were downregulated in the case group at day three. However, their expression became higher at day seven. Diabetic glucose concentration inhibits normal proliferation and cardiac differentiation of MSCs. This effect should be considered in stem cell therapy of cardiovascular patients who are concurrently affected by hyperglycemia, a common comorbidity in such individuals. Why carry out this study?•Stem cell therapy has opened a promising window to reduce great burden imposed by cardiovascular disease.•Despite substantial benefits observed in early studies, clinical translation of such treatment approaches have been hampered.•Hyperglycemic condition may be one of the hurdles responsible for reduced beneficial effects of stem cell therapy in cardiovascular patients. What was learned from the study? •of our study revealed that diabetic glucose concentration inhibits normal proliferation and cardiac differentiation of mesenchymal stem cells.•Since diabetes is one of the common comorbidity in patients with cardiovascular diseases, glycemic status of such patients should